JAK1 and Alzheimer disease: Other innovative treatments include oral inhibitors of Janus kinase (JAK), another pathway that has been shown to be involved in the pathogenesis of AD [7]: Baricitinib (JAK1,2 inhibitor), Upadacitinib, and Abrocitinib (specific JAK1 inhibitors) [2,8].